Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Prognosys Biosciences Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners, showing some concentration within the personnel reviewing the company's applications. For a practitioner, this means that the company can potentially leverage a more consistent prosecution strategy, as some examiners may be handling multiple cases. The 4 pending office actions are distributed across 2 distinct art units, indicating that the company's filings are focused within a few specialized technical groups at the USPTO.
The busiest examiner is CROW, ROBERT THOMAS, who is responsible for 2 pending office actions. This indicates that 2 of the 4 pending office actions are concentrated under a single individual. This concentration within 2 distinct art units allows for a more targeted approach to prosecution, as the practitioner can focus on the specific standards and tendencies of a smaller group of examiners. Practitioners should prioritize understanding the historical rulings of CROW, ROBERT THOMAS, as this examiner's decisions will have a significant impact on the overall success of the company's current patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CROW, ROBERT THOMAS | 2 | 41.6% | +32.5% |
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
| PARISI, JESSICA DANIELLE | 1 | 75.0% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264491 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | — |
| 19264527 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | — |
| 19021456 | METHODS AND SYSTEMS FOR DETERMINING SPATIAL PATTERNS OF BIOLOGICAL TARGETS IN A SAMPLE | OLSON, ALEXANDRA NADINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19264491 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | — |
| 19264527 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | — |
| 18414337 | METHODS FOR DETECTING PEPTIDE/MHC/TCR BINDING | PARISI, JESSICA DANIELLE | — |
| Art Unit | Apps |
|---|---|
| 1683 | 2 |
| 1684 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19264491 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | 1683 | §103§112 | Final Rejection | — | Pending | Jul 09, 2025 |
| 19264527 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | CROW, ROBERT THOMAS | 1683 | §103§112 | Final Rejection | — | Pending | Jul 09, 2025 |
| 19021456 | METHODS AND SYSTEMS FOR DETERMINING SPATIAL PATTERNS OF BIOLOGICAL TARGETS IN A SAMPLE | OLSON, ALEXANDRA NADINE | 1684 | §101§112Other | Non-Final OA | — | Pending | Jan 15, 2025 |
| 18414337 | METHODS FOR DETECTING PEPTIDE/MHC/TCR BINDING | PARISI, JESSICA DANIELLE | 1684 | §102DP | Non-Final OA | — | Pending | Jan 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrognosys Biosciences Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Robert Thomas Crow has the most, with 2 of Prognosys Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
